🇺🇸 FDA
Pipeline program

Sintilimab with Interleukin-2+CAPOX

PRSYM202310

Phase 2 small_molecule completed

Quick answer

Sintilimab with Interleukin-2+CAPOX for Locally Advanced Rectal Adenocarcinoma is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Locally Advanced Rectal Adenocarcinoma
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials